B Bus, Grad Dip HSM, MBL, FCHSM, GAICD
Simon is an experienced non-executive director with expertise in governance, infrastructure and project management. Over a 35 year period he held executive roles at a number of Melbourne health organisations with a portfolio responsibility for strategic and service planning, clinical and non-clinical services, infrastructure, facilities and project management.
Simon was appointed to the board of the Royal Victorian Eye and Ear Hospital in 2017 and is Deputy Chair, Chair of the Audit and Risk Committee and member of the Quality & Safety Committee. He is also Deputy Chair of Uniting AgeWell and chair of the board Property & Development and Governance Committees. He is a past president of the Australasian College of Health Service Management (Victorian Branch) and a Graduate of the Australia Institute of Company Directors.
Andrew Cowlishaw (Treasurer, Chair Finance and Risk Committee)
B.Comm (Accounting and Finance), CA
Andrew is an experienced finance executive, with 21 years’ experience across corporate finance, strategy and operations. He is a Partner of Ernst & Young, where he leads the Melbourne Mergers & Acquisitions practice group. Andrew focuses on the healthcare, education and financial sponsors industry sectors. He has been a non executive director of numerous private high growth companies and has worked extensively with management teams and boards in setting strategies and driving operational improvements.
Professor Andrew Cuthbertson AO
BMedSci, MBBS, PhD FTSE FAHMS
Professor Cuthbertson is Chief Scientific Officer and Director, Research and Development for CSL Limited. In 2016 he was made an Enterprise Professor, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne and an Officer of the Order of Australia for his services to medical research.
Ba. Soc. Sc., Post Grad. Cert. Public Sector Management, M. Health Admin, Graduate Australian Institute of Company Directors
Christine has extensive experience in the health, community and philanthropic sectors in Western Australia, Tasmania and Victoria. Christine has been the CEO of two hospitals in Victoria, leading the delivery of aged and palliative care services. Christine is currently a consultant in philanthropy, and most recently was the Chief Executive Officer of The Myer Foundation and Sidney Myer Fund. Christine holds a number of Directorship and Advisory positions, and provides strategic philanthropic advice to community-based organisations.
Olivia Hilton (Chair)
Bbus (Mkt) Hons
Olivia is the Founder and Director of a social impact advisory business.
Prior to this Olivia was the Executive Director at Social Ventures Australia (SVA) for over 10 years, leading the Consulting business. Olivia has deep experience supporting organisations, governments and philanthropists who are driving social change on issues of strategy, measurement and evaluation and governance.
Olivia is a former CEO of an Australian publicly listed communications company, where she devised, led and managed the company’s strategy and day-to-day operations, including a staff of 100 employees in five countries. She has extensive experience in strategy development, implementation, communications and operations.
Olivia is also a Director of Chuffed.org a global crowd funding platform.
Professor Keith Martin (Managing Director)
MA BM BCh DM MRCP FRCOphth FRANZCO ALCM
Keith Martin is Managing Director of the Centre for Eye Research Australia (CERA) and Ringland Anderson Professor and Head of Ophthalmology at the University of Melbourne.
Clinically, Professor Martin specialises in the medical and surgical management of complex glaucoma. He is currently President of the World Glaucoma Association, the largest glaucoma organisation in the world.
Professor Martin is working to develop new treatments for eye disease using stem cells, gene therapy and other techniques as a Principal Investigator at CERA. He is also co-founder of Quethera, a Cambridge-based gene therapy company which has developed a gene therapy for glaucoma that is currently progressing towards human clinical trials.
BA, LLB (Hons)
Wendy is an experienced corporate and commercial lawyer. She is currently a Special Counsel at Thomson Geer Lawyers, having previously held senior in-house legal, strategy and governance roles. Wendy has deep experience working with boards of directors and senior management teams on governance and compliance matters as well as strategic partnerships, joint ventures, restructures, mergers and acquisitions, fundraising, major procurement projects and complex contracting. Wendy is an experienced non-executive director and in addition to being a member of the board of CERA, is also a member of the Finance and Risk Committee and the board of the CERA Foundation.
Professor John Prins
MB, BS, PhD, FRACP, FAHMS
Professor John Prins is an active clinician-scientist, a key opinion leader in diabetes and endocrinology in Australia, and he sits on numerous national and international scientific, clinical and educational committees and boards for the National Health and Medical Research Council (NHMRC), non-government organisations and industry.
In 2018 Professor Prins was appointed Head of the Melbourne Medical School and Professor of Medicine at the University of Melbourne. He also has part-time clinical appointments in Endocrinology at the Royal Melbourne Hospital, Goulburn Valley Health and Rumbalara.
Professor Prins has substantial commercialisation experience, holds four international patents and was founder and scientific director of a spin-out biotech company — Adipogen Pty Ltd. He sits on numerous Australian and Global Pharmaceutical Scientific & Clinical Advisory Boards.
Professor Prins is actively involved in undergraduate and post-graduate teaching and training and has ongoing research interests in obesity, diabetes and intellectual disability. His current research focus is early-stage drug development in Type 2 Diabetes and in Non-Alcoholic Fatty Liver Disease. His research has attracted substantial government, NGO and Industry funding and he has published over 150 papers.
Suwanee is an investment adviser at Macquarie with 21 years experience in advising philanthropists, business founders, medical and other professional specialists and not-for-profits on investments. Suwanee is committed to helping: develop medical research capacity to provide early warning, intervention and reduction of global health risks particularly preventable risks, and fair access to cost-effective medical treatment.
Suwanee is also a non-executive director and member of The Diplomacy Training program committed to advancing human rights and empowering civil society in the Asia Pacific region through education, training, and building of skills and capacity in non-governmental organisations and individual human rights defenders.
Professor Darren Kelly
Darren is the Associate Dean (Innovation and Enterprise, MDHS) at The University of Melbourne and the Director of Biomedical Research in the Department of Medicine, St Vincent’s Hospital Melbourne, where his research expertise lies in progressing pre-clinical novel interventions and developing experimental models of cardiovascular disease.
Concurrent to his role with The University of Melbourne, Darren is the CEO and Managing Director of Certa Therapeutics and Occurx, Australia, bringing over 25 years of management and research expertise in the life sciences and biotech sector. He has published over 200 manuscripts in the field of translational research and novel interventions many of which have had a direct impact on human disease.
In 2009, Darren was a recipient of the prestigious TJ Neale award for outstanding contribution to nephrology. In 2015 Darren joined the Medical Research Commercialisation Fund as Venture Partner. Darren has proven history in translational research. He was previously Founder, CEO and Director of Fibrotech Therapeutics, a company that developed orally active anti-fibrotic inhibitors to treat underlying pathological fibrosis in kidney and heart failure, which was ultimately acquired by Shire Plc for a record 75 million USD upfront including milestone payments up to 600 million USD.
Darren has a PhD in Translational Medicine from the University of Melbourne. He is a current member of the Australian Institute of Company Directors, AusBiotech, BioMelbourne Network and a Fellow of the American Society of Nephrology.